The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2020 | Results of a site-manufactured anti-CD19 CAR-T in nHL
Marcos de Lima, MD, UH Cleveland Medical Center, Cleveland, OH, discusses the results of a study evaluating a second-generation anti-CD19 CAR-T construct consisting of a 4-1BB co-stimulatory domain in heavily pre-treated non-Hodgkin lymphoma (nHL) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
